Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study

Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study

Background and aimThe purpose of this study was to investigate and validate the efficacy of a nomogram model in predicting early objective response rate (ORR) in u-HCC patients receiving a combination of TACE, Lenvatinib, and anti-PD-1 antibody treatment after 3 months (triple therapy).MethodThis st...

Full description

Bibliographic Details
Main Authors: Shuqun Li, Junyi Wu, Jiayi Wu, Yangkai Fu, Zhenxin Zeng, Yinan Li, Han Li, Weijia Liao, Maolin Yan
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Immunology
Subjects:
unresectable hepatocellular carcinoma
TACE
levantinib
anti-PD-1 antibody
immunotherapy
nomogram
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1109771/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1109771/full

Similar Items